Baxter’s Amia Automated Home Dialysis System Receives FDA Clearance
Baxter received FDA 510(k) clearance in October for Amia, a home-based automated peritoneal dialysis system that features voice guidance, touchscreen control and two-way connectivity. With more than 600,000 people in the US living with end-stage renal disease, and 40,000 of these on peritoneal dialysis, the company is working to enhance renal care with patient-centric technologies that provide more individualized and efficient home-based therapy.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.